Anti-fibrotic effects of curcumin and some of its analogues in the heart

Armita Mahdavi Gorabi, Saeideh Hajighasemi, Nasim Kiaie, Giuseppe M.C. Rosano, Thozhukat Sathyapalan, Khalid Al-Rasadi, Amirhossein Sahebkar*

*Corresponding author for this work

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Cardiac fibrosis stems from the changes in the expression of fibrotic genes in cardiac fibroblasts (CFs) in response to the tissue damage induced by various cardiovascular diseases (CVDs) leading to their transformation into active myofibroblasts, which produce high amounts of extracellular matrix (ECM) proteins leading, in turn, to excessive deposition of ECM in cardiac tissue. The excessive accumulation of ECM elements causes heart stiffness, tissue scarring, electrical conduction disruption and finally cardiac dysfunction and heart failure. Curcumin (Cur; also known as diferuloylmethane) is a polyphenol compound extracted from rhizomes of Curcuma longa with an influence on an extensive spectrum of biological phenomena including cell proliferation, differentiation, inflammation, pathogenesis, chemoprevention, apoptosis, angiogenesis and cardiac pathological changes. Cumulative evidence has suggested a beneficial role for Cur in improving disrupted cardiac function developed by cardiac fibrosis by establishing a balance between degradation and synthesis of ECM components. There are various molecular mechanisms contributing to the development of cardiac fibrosis. We presented a review of Cur effects on cardiac fibrosis and the discovered underlying mechanisms by them Cur interact to establish its cardio-protective effects.

Original languageEnglish
Pages (from-to)731-743
Number of pages13
JournalHeart Failure Reviews
Volume25
Issue number5
DOIs
Publication statusPublished - Sep 1 2020
Externally publishedYes

Keywords

  • C66
  • Cardiac fibrosis
  • Curcumin
  • Diferuloylmethane
  • J19

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this